Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
about
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Non-mammalian models of multiple endocrine neoplasia type 2.Recent advances in the biology and therapy of medullary thyroid carcinoma.A secondary RET mutation in the activation loop conferring resistance to vandetanib.Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.RET rearrangements are actionable alterations in breast cancer
P2860
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
@en
type
label
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
@en
prefLabel
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
@en
P2093
P2860
P50
P1476
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
@en
P2093
André Richters
Carina Lorenz
Daniel Schütte
Frauke Leenders
Georg Pall
Joachim Diebold
Julian Engel
Jürgen Wolf
Kevan M Shokat
Marcel A Dammert
P2860
P356
10.1126/SCITRANSLMED.AAH6144
P407
P50
P577
2017-06-01T00:00:00Z